You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Details for Patent: 7,488,469


✉ Email this page to a colleague

« Back to Dashboard


Title:Delivery of caffeine through an inhalation route
Abstract: The present invention relates to the delivery of caffeine through an inhalation route. Specifically, it relates to aerosols containing caffeine that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of caffeine. In a method aspect of the present invention, caffeine is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of caffeine, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal. In a kit aspect of the present invention, a kit for delivering caffeine through an inhalation route to a mammal is provided which comprises: a) a composition comprising at least 5 percent by weight of caffeine; and, b) a device that forms a caffeine containing aerosol from the composition, for inhalation by the mammal.
Inventor(s): Rabinowitz; Joshua D (Princeton, NJ)
Assignee: Alexza Pharmaceuticals, Inc. (Mountain View, CA)
Filing Date:Jul 18, 2006
Application Number:11/488,302
Claims:1. A condensation aerosol for delivery of caffeine formed by heating a composition containing caffeine coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of caffeine and less than 5 percent by weight of caffeine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

2. The condensation aerosol according to claim 1, wherein the condensation aerosol has an MMAD of less than 3 microns.

3. The condensation aerosol according to claim 1 or claim 2, wherein the condensation aerosol has an MMAD of less than 2 microns.

4. A method of forming a caffeine containing aerosol comprising: (a) heating a composition containing caffeine coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of caffeine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

5. The method according to claim 4, wherein the condensation aerosol has an MMAD of less than 3 microns.

6. The method according to claim 5, wherein the coated composition comprises at least 10 percent by weight of caffeine.

7. A method of forming a caffeine containing aerosol comprising: (a) heating a composition containing caffeine and a pharmaceutically acceptable excipient coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of caffeine and less than 5 percent by weight of caffeine degradation products and the condensation aerosol has an MMAD of less than 5 microns.

8. The method according to claim 7, wherein the condensation aerosol has an MMAD of less than 3 microns.

9. The method according to claim 8, wherein the coated composition comprises at least 10 percent by weight of caffeine.

10. The method according to claim 8, wherein the condensing comprises allowing the vapor to cool.

11. The condensation aerosol according to claim 2, wherein the condensing comprises allowing the vapor to cool.

12. The method according to claim 5, wherein the condensing comprises allowing the vapor to cool.

13. A method of forming a caffeine containing aerosol comprising: (a) heating a composition containing caffeine coated on a solid support to form a vapor, and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the condensation aerosol is formed at a rate greater than 1 mg/second, and wherein the particles comprise at least 10 percent by weight of caffeine and less than 5 percent by weight of caffeine degradation products, and the condensation aerosol has an MMAD less than 5 microns.

14. The method according to claim 13, wherein the condensation aerosol has an MMAD of less than 3 microns.

15. The method according to claim 14, wherein the condensation aerosol is formed at a rate greater than 5 mg/second.

16. The method according to claim 15, wherein the condensation aerosol is formed at a rate greater than 20 mg/second.

17. The method according to claim 13, wherein the condensing comprises allowing the vapor to cool.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.